SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

The Dogecoin community is abuzz with speculation over its potential integration into Elon Musk's X platform for payments, driving fervent hopes for a significant rally while others caution against market volatility.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is experiencing strong upward momentum, with the crypto community enthusiastically discussing a "meme coin season" and its potential for significant gains, often framing it as the "alpha frog" in a broader "three frog narrative."

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst widespread community discussion of a potential 'meme coin season,' with many comparing its performance to other surging meme tokens like PEPE and DOGE while a significant portion of the community expresses frustration and skepticism regarding its long-term viability.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the FDA granted Priority Review for AXS-05 to treat Alzheimer's disease agitation, with an April PDUFA date, fueling community optimism alongside robust sales growth for its major depressive disorder treatment, Auvelity. Investors are keenly discussing the significant market potential for its expanding neuroscience pipeline and the company's strong commercial execution, with many anticipating substantial share appreciation.

Ramaco Resources, Inc. engages in the operation and development of coal mining properties. The firm deals with metallurgical coal in central and southern West Virginia, southwestern Virginia and southwestern Pennsylvania. Its portfolio consists of Elk Creek, Berwind, RAM Mine, and Knox Creek. The company was founded by Randall W. Atkins in August 2015 and is headquartered in Lexington, KY.

Ramaco Resources Inc - Ordinary Shares - Class A

Ramaco Resources Inc

Ramaco Resources is trending due to high anticipation for the upcoming Critical Minerals Summit, with the community actively discussing potential U.S. government investment in domestic critical mineral producers and the company's unique position with its Brook Mine rare earth project, further boosted by a recent analyst upgrade despite past volatility over potential price floor policies.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as its preliminary financial results highlight strong initial sales for Tonmya, prompting community discussion about the new fibromyalgia treatment's promising launch trajectory compared to other CNS drugs. Despite historical concerns regarding dilution, increasing institutional ownership and the company's significant cash reserves are driving a narrative that the stock is currently undervalued given Tonmya's commercial traction and pipeline potential.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Saakuru

Despite confusion around its ticker identity on some platforms, the crypto community is actively discussing a token, widely believed to be the "Seeker Solana Smartphone Token," following its new listings on major exchanges and recent airdrops to Solana phone owners. This asset is experiencing significant momentum, drawing comparisons to past Solana ecosystem pumps, while some caution about potential profit-taking and volatility.

BlockDAG

BlockDAG is trending as its community grapples with continuous, often conflicting, announcements regarding its mainnet launch and exchange listings, leading to widespread speculation and frustration over perceived delays, lost coins, and concerns about the project's overall legitimacy as a presale.

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio Inc.

Upstream Bio is trending due to a significant market sell-off following its Phase 2 VALIANT trial results for verekitug in severe asthma. Although the drug showed strong efficacy with quarterly dosing, the community is debating an 'overreaction' because the highly anticipated biannual dosing did not meet market expectations, with many investors now viewing it as a dip-buying opportunity.

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is at the center of investor discussion following multiple strong earnings beats and strategic collaborations, notably with NVIDIA for AI-driven lab automation, pointing to robust future growth in the life sciences sector. Despite recent "brutal downward movement" in its stock price, the community is weighing these positive catalysts and numerous analyst upgrades against broader market softness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting PR...

<ul class="summary-bullets"><li>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.</li><li>The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.</li><li>Some of the symptoms of ichthyosis vulgaris include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or stomach.</li></ul>Azitra Inc. (AZTR) on Monday announced positive preclinical data for its ATR-01 program, which is designed to treat ichthyosis vulgaris, a skin disorder that most often appears in early childhood.<h2 class="st-heading-2">Ichthyosis Vulgaris Affects 1.3 Million People In The U.S.</h2>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder. The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.<blockquote>“We are optimistic that this innovative, topically delivered treatment option has the potential to directly address the disease pathophysiology. We look forward to further updates on this program in 2026, including details around a path to first-in-human studies."– Francisco Salva, CEO, Azitra</blockquote><a href="https://stocktwits.com/symbol/AZTR">Azitra shares</a> soared more than 56% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Is Ichthyosis Vulgaris?</h2>Ichthyosis vulgaris is a common skin disorder that causes dry, scaly skin. Some of the symptoms include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or the stomach,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://my.clevelandclinic.org/health/diseases/21069-ichthyosis-vulgaris">according</a> to the Cleveland Clinic. Some of the options available to manage these symptoms include frequent moisturization using topical exfoliants or oral retinoids in severe cases.Get updates to this story developing <a href="https://stocktwits.com/news-articles/markets/equity/azitra-shares-soar-premarket-positive-preclinical-data-ichthyosis-vulgaris/ch6CHUIR3Ym">directly on Stocktwits</a>.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-up-major-earnings-week/ch6CM53R3Yh">Dow Futures Edge Up As Investors Turn Attention To Major Earnings Week: AMZN, BA, NVDA, ZION Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Azitra Shares Soar Pre-Market: What’s Driving The Surge?

Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.

Equity

Azitra had its best trading day in more than seven months on Wednesday after disclosing that the first patient had been dosed in its Phase 1/2 trial of ATR04-484, a topical live biotherapeutic being developed to treat rashes caused by EGFR inhibitor (EGFRi) cancer therapies.The stock closed Wednesday up 35.9% at $1.03, before slipping 2.4% in after-hours trading.ATR04-484, which has a fast-track designation from the FDA, is designed to address EGFRi-associated rash, a side effect that affects an estimated 150,000 people in the U.S. each year.&nbsp;These rashes are one of the most common and disruptive side effects of EGFRi cancer drugs, occurring in up to 80% of patients and often severe enough to interrupt treatment.“Dosing the first patient is an important milestone in the advancement of ATR04-484 as a potential treatment for EGFRi-associated rash,” said CEO Francisco Salva. He noted the therapy could help reduce the dermatologic toxicities that limit&nbsp;the use of targeted cancer therapies such as those for lung and colorectal cancers.The randomized, double-blind, vehicle-controlled Phase 1/2 study will evaluate ATR04-484’s safety, tolerability, and efficacy in adult patients, measuring endpoints such as rash severity, itch, and pain.&nbsp;The drug is based on an engineered strain of Staphylococcus epidermidis, designed to reduce IL-36γ and S. aureus levels, both of which are elevated in EGFRi-related rashes.Beyond ATR04-484, Azitra is also advancing ATR-12 for Netherton syndrome, a rare and life-threatening genetic skin disease with no approved therapies. Both programs stem from the company’s dermatology platform, which leverages a microbial strain library and artificial intelligence to identify new drug candidates.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,657% surge in 24-hour message volume.One user said that Azitra shares had been “holding pretty strong,” while others pointed to the surge in trading activity.&nbsp;<stembedurl>https://stocktwits.com/TheStocksDoc/message/626774494</stembedurl><stembedurl>https://stocktwits.com/Thunderman/message/626784109</stembedurl>Wednesday’s turnover reached 110.7 million shares, more than 800 times the stock’s average daily volume of about 132,000.<a href="https://stocktwits.com/symbol/AZTR">Azitra’s stock</a> has declined 63.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra’s stock (AZTR) has declined 63.7% so far in 2025. (Photo credit: Getty Images)

Azitra Stock Scores Best Day In 7 Months After First Patient Dosed In Cancer-Linked Skin Rash Trial

The FDA has granted the program Fast Track status, aiming to address rashes that affect roughly 150,000 U.S. patients each year.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday morning after it announced two developments on Tuesday. The firm said the US Patent and Trademark Office (USPTO) has granted a patent that covers future potential pipeline candidates for indications including atopic dermatitis.Apart from this, the company also announced three additional newly allowed patents in three countries, including the US, Canada, and China. Following the announcement, the stock had closed over 200% higher on Tuesday. However, a large portion of the gains were pared in Wednesday’s pre-market session with the stock losing over 75% ahead of the market open.Following the development, the stock gained a lot of traction on Stocktwits. Tuesday’s page views for the symbol on Stocktwits stood at 220x their daily average of the previous month. Total user messages on the Azitra symbol page grew from a handful per day to over 1,000 on Tuesday while total number of users with the stock symbol on their watchlist grew by nearly 1,000 to roughly 1,600 as of Wednesday morning.The firm expressed optimism about its new patents. Azitra’s COO and co-founder Travis Whitfill pointed out that atopic dermatitis affects approximately 16.50 million people in the United States. “There are numerous diseases associated with filaggrin deficiency, and the newly issued U.S. patent extends our protection to include a major market in the U.S., atopic dermatitis, particularly those with mild to moderate disease. Additionally, the new patent allowances in China and Canada extend our IP strength globally,” he said.Meanwhile, the firm also announced a $10 million fundraise via common shares and warrants priced at $1.50. The company said it intends to use the net proceeds from this offering for working capital and general corporate purposes, but the dilution is weighing heavily on shares Wednesday morning.Stocktwits users are chatting about the stock’s sudden dip after Tuesday’s optimism. One user named “dt2011” pointed out the benefits of taking profits when opportunity allows.<figure class="image"><a href="https://stocktwits.com/dt2011/message/580521550"><img style="aspect-ratio:815/263;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_9_18_29_AM_8c732d9994.png" alt="Stocktwits user dt2011's post on Azitra Inc" width="815" height="263"></a><figcaption>Stocktwits user dt2011's post on Azitra Inc</figcaption></figure>

Azitra Stock Witnesses 220x Page Views On Stocktwits After These Developments 

The stock closed over 200% higher on Tuesday after the firm reported multiple patent wins. Still, investors are not very enthused with the company’s latest public offering worth $10 million

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

Azitra Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.32	--	--	N/A
Q3 '25	-$0.76	-$0.67	11.84%	BEAT
Q2 '25	-$0.21	-$1.20	-470.86%	MISSED
Q1 '25	--	-$0.23	--	N/A
Q4 '24	-$0.31	--	--	N/A

AZTR
Azitra Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest AZTR News

AZTRAzitra Inc